Press Releases May 13, 2026 04:05 PM

Teekay Tankers Ltd. Reports First Quarter 2026 Results; and Declares Dividends

Teekay Tankers Reports Q1 2026 Financial Results and Declares Both Regular and Special Dividends

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
TNK

Teekay Tankers Ltd. announced its financial results for the first quarter ended March 31, 2026, and declared a fixed quarterly cash dividend of $0.25 per share alongside a special cash dividend of $1.00 per share, payable June 2, 2026. The company operates a fleet of 33 double-hull tankers and provides marine services, including ship-to-ship transfer operations in the U.S. Gulf and Caribbean.

Teekay Tankers Ltd. Reports First Quarter 2026 Results; and Declares Dividends
TNK
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Declared fixed quarterly dividend of $0.25 and a special dividend of $1.00 per share, indicating strong cash flow.
  • Operates a sizable fleet of 33 double-hull tankers, engaging in spot market trading and fixed-rate time charters.
  • Provides marine services including ship-to-ship transfer operations in the U.S. Gulf and Caribbean, enhancing operational scope.

HAMILTON, Bermuda, May 13, 2026 (GLOBE NEWSWIRE) -- Teekay Tankers Ltd. (Teekay Tankers or the Company) (NYSE: TNK) today reported the Company's results for the three months ended March 31, 2026 and announced that its Board of Directors has declared its fixed quarterly cash dividend of $0.25 per share for the quarter ended March 31, 2025. In addition, the Board of Directors has declared a special cash dividend of $1.00 per share. The cash dividends are payable on June 2, 2026 to all shareholders of record as at May 26, 2026.

The full earnings release and Teekay Group’s earnings presentation are available on the Company’s website here.

About Teekay Tankers

Teekay Tankers has a fleet of 33 double-hull tankers (including 14 Suezmax tankers, 18 Aframax / LR2 tankers, and 1 VLCC tanker), and also has three time chartered-in oil and product tankers. Teekay Tankers’ vessels are typically employed through a mix of spot tanker market trading and short- or medium-term fixed-rate time charter contracts. In addition, Teekay Tankers manages and operates vessels for the Australian Government and Australian energy companies as part of the marine services provided by the Company and owns a ship-to-ship transfer business that performs full service lightering and lightering support operations in the U.S. Gulf and Caribbean. Teekay Tankers was formed in December 2007 by Teekay Corporation Ltd.

Teekay Tankers’ Class A common shares trade on the New York Stock Exchange under the symbol “TNK.”

For Investor Relations
enquiries contact:

E-mail: investor.relations@teekay.com
Website: www.teekay.com


Risks

  • Dependence on the volatile spot tanker market and time charter contracts, which can be subject to shipping demand fluctuations.
  • Exposure to global oil and product shipping demand impacted by geopolitical and economic conditions.
  • Potential operational risks associated with marine services and ship-to-ship transfers in sensitive regions like the U.S. Gulf and Caribbean.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026